Jazz Pharmaceuticals PLC (JAZZ) Stock Forecast & Price Target
Jazz Pharmaceuticals PLC · NASDAQ
$256.92+1.49 (+0.58%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 17 firms covering Jazz Pharmaceuticals PLC, 16 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $185.00 to $307.00, a moderate spread. The average target of $256.59 is roughly in line with the current $256.92. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 12 to 16 over recent months. On the fundamentals, the Street sees consensus EPS building from about $6.37 next quarter toward $25.72 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS17 ratings
Moderate Buy
Strong Buy00%
Buy1694%
Hold16%
Sell00%
Strong Sell00%
Based on 17 analysts giving stock ratings to Jazz Pharmaceuticals PLC.
As of Jul, 16 of 17 firms rate JAZZ a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
JAZZ EPS & revenue forecast
EPS · NEXT QUARTER
$6.37
Range $5.96 – $6.78 · 17 analysts · -22% YoY
Next period, 17 analysts expect Jazz Pharmaceuticals PLC to earn $6.37 a share (range $5.96 – $6.78), versus $8.13 a year earlier. Full-year consensus is $25.31, growing to $25.72 the year after.
REVENUE · NEXT QUARTER
$1.2B
Range $1.1B – $1.2B · 17 analysts · +2% YoY
Revenue is expected to reach $1.2B (range $1.1B – $1.2B), +2.3% year-over-year. Full-year consensus is $4.5B, rising to $4.8B next year.
Top analysts covering Jazz Pharmaceuticals PLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on JAZZ.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #12
Buy
$226.00-12.0% to target
Overall win rate
61%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #64
Buy
No targeton JAZZ
Overall win rate
52%
+ Follow
#3
Leonid Timashev
RBC Capital · Rank #69
Buy
$258.00+0.4% to target
Overall win rate
42%
+ Follow
#4
Ami Fadia
Needham · Rank #90
Buy
$282.00+9.8% to target
Overall win rate
46%
+ Follow
#5
David Amsellem
Piper Sandler · Rank #95
Buy
$301.00+17.2% to target
Overall win rate
50%
+ Follow
JAZZ stock forecast FAQ
What is JAZZ's average 12-month price target?+
The 17 analysts with a live target average $256.59 for Jazz Pharmaceuticals PLC over the next 12 months, ranging from a $307.00 high to a $185.00 low.
Is JAZZ stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 17 analyst ratings, 16 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for JAZZ?+
The Street-high target is $307.00 (B of A Securities), and the Street-low is $185.00 (Goldman Sachs). The average of all 17 active targets is $256.59.
How many Wall Street analysts cover JAZZ?+
17 analysts have an active rating on Jazz Pharmaceuticals PLC, and 17 firms carry a live 12-month price target.
Who is the most accurate analyst covering JAZZ?+
Among analysts who currently cover JAZZ, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #12). Their current call is Buy with a $226.00 target.
What is Jazz Pharmaceuticals PLC's projected EPS for next quarter?+
The consensus estimate is $6.37 per share (range $5.96 – $6.78) across 17 analysts. Full-year EPS is projected at $25.31, rising to $25.72 the following year.
How much revenue is Jazz Pharmaceuticals PLC expected to report next quarter?+
Consensus revenue is $1.2B (range $1.1B – $1.2B). Full-year revenue is projected at $4.5B, growing to $4.8B next year.
Have analysts been upgrading or downgrading JAZZ lately?+
As of Jul, 16 of 17 firms rate JAZZ a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their JAZZ calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Deutsche Bank
